Biomarkers and outcomes for pembrolizumab/axitinib for kidney cancer
In this phase 1b study, he researchers were looking for a relationship between biomarkers found in the blood and outcomes following treatment with a combination pembrolizumab plus axitinib for advanced renal cell carcinoma (RCC). They found that high levels of a T cell protein receptor called CD8 in the kidney tumour at baseline were associated […]